Date: Tuesday Sept 30, 2014
In the past, differential profiling and functional studies of microRNA (miRNA) has been performed mainly using tissues samples collected by invasive methods. However, in a clinical setting, more convenient and non-invasive methods are required, such as collection of peripheral blood or other bodily fluids. Recently, it has been demonstrated that miRNAs are present in circulating blood plasma, both free circulating and within exosomes, as well as within other biofluids such as cerebral spinal fluid, urine and even breast milk. These circulating miRNAs represent a potential new approach for diagnostic screening. [click to continue…]
Incoming search terms for this article:
September 18, 2013 / B3C newswire / - Major new funding for research into epilepsy is announced today. The EpimiRNA Consortium, involving 16 partners from 8 European countries, the USA and Brazil has received €11.5 million funding from the European Union’s Framework Programme 7 to investigate molecular mechanisms, diagnostics and treatments for epilepsy.
Over 50 million people across the world suffer from epilepsy, making it the most common serious neurological disorder for which there is no cure. The causes for epilepsy are insufficiently understood with currently available treatments being sub-optimal and with a significant proportion of patients not responding. Recent discoveries have identified a new type of molecule in cells called microRNA which may be critical to controlling the changes in brain chemistry that accompany the development and course of epilepsy. The EpimiRNA Consortium represents a major interdisciplinary effort between epilepsy researchers, geneticists, clinicians, experts in advanced molecular sciences and research-active companies working together to understand molecular mechanisms, diagnostics and developing novel microRNA-based therapeutics to prevent the development of epilepsy, the occurrence of seizures or reverse epilepsy once established.
Prof. David Henshall, Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Coordinator of the EpimiRNA consortium comments: “Improved understanding of the causes of epilepsy is critical to [click to continue…]
Product innovation and the development of high-qualitative assays are the need of the hour
LONDON, Sept. 4, 2013 /PRNewswire/ — Rapid growth in microRNA (miRNA) research over the past two years, owing to its diagnostic and therapeutic potential, has fueled development in the global miRNA tools and services market. Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays and functional tools, qRT PCR remains the fastest-growing, while microarray is gradually being replaced by next-generation sequencing platforms.
New analysis from Frost & Sullivan (http://www.frost.com/prod/servlet/svcg.pag/HCLS), Global Analysis of MicroRNA Tools and Services Market, finds that the tools side of the market earned revenues of $110.0 million in 2012 and estimates this to more than double to reach $247.7 million in 2017. The US contributed to about 47% of the revenue followed by 36.7% from Europe, while leaving the rest to APAC and ROW. The miRNA services market earned revenues of $35.1 million in 2012 and this is expected to grow to $63.3 million in 2017. The end users covered are academic and research institutes, core facilities, and pharmaceutical and biotech companies.
The growth of therapeutic and diagnostic enterprises, higher research funding and increased outsourcing to contract research organizations in the US will present immense opportunities for the miRNA tools and services market. At the same time, [click to continue…]
Call for papers for an open special issue on small/microRNAs:
Small RNAs: Revolutionizing the Genomics Landscape
The editors invite researchers to contribute original research articles as well as review articles focused on the use, development, or the application of genomics tools for investigating the role of small RNAs at the whole-genome level. The editors will be interested in review manuscripts that describe biology of noncoding RNAs as well as bioinformatics and computational biology based approaches for analyzing small RNAs datasets.
Potential topics include, but are not limited to:
- Small RNAs and microRNAs next-generation sequencing data analysis
- Identification and classification of miRNA genes and targets
- Small RNAs regulatory networksSoftware and tool development for small RNA data analysis
- Comparative evolution of small RNAs
- Small RNAs players in cancer and plant stress responses
Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ijg/guidelines/.
Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ijg/rnas/ according to the following timetable:
- Manuscript Due: Friday, 2 August 2013
- First Round of Reviews: Friday, 25 October 2013
- Publication Date: Friday, 20 December 2013
For the full details please see: